{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:37Z","timestamp":1753891957548,"version":"3.41.2"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>EBV associated lymphoproliferative disorders (EBV LPD) are a known complication following solid organ or hematopoietic stem cell transplantation. The disturbance of the immune system leads to a lack of control of latent EBV-infected B-cells, as control by T-cells is mandatory to prevent uninhibited cell proliferation. EBV LPD in other settings is less frequent and etiology and pathogenesis are not completely understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>We present the case of an 18-year old adolescent suffering from lymphoblastic T-cell lymphoma who developed a life-threatening EBV associated B-cell lymphoma while he was under therapy with 6-MP (6- mercaptopurine). An underlying homozygous TPMT (thiopurine S-methyltransferase) deficiency with subsequent insufficient degradation of 6-MP was identified as contributory for the development of a distinct lymphopenia leading to EBV LPD. The patient was successfully treated by discontinuation of 6-MP and initiating rituximab monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Rare cases of EBV LPD during therapy with 6-MP are reported in patients with leukemia, but no data about TPMT pharmacogenomics are available. In contrast the disease development in the presented case may be explained by the iatrogenic immunosuppression in the context of TPMT deficiency. While using 6-MP testing of genetic variations is not required for every protocol, although the use of thiopurines in patients with TPMT deficiency can cause severe immunosuppression. Our case suggests that insufficient degradation of 6-MP can have significant consequences despite dose reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>When using thiopurines, TPMT genetics should be initiated and strict drug monitoring and dose adjusting must be performed by a specialized center.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.881612","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T06:56:21Z","timestamp":1651820181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Multifocal EBV-Associated Diffuse Large B-Cell Lymphoma in a Patient With 6-MP Associated Lymphopenia With TPMT Deficiency"],"prefix":"10.3389","volume":"10","author":[{"given":"Lara","family":"M\u00fcller-Scholden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Deinlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eyrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Gerhardt","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Wiegering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"W\u00f6lfl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1038\/emm.2014.82","article-title":"EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management","volume":"47","author":"Ok","year":"2015","journal-title":"Exp Mol Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/pbc.26102","article-title":"Facial manifestations of Epstein-Barr virus-related lymphoproliferative disease in childhood acute lymphoblastic leukemia in remission: two atypical presentations","volume":"63","author":"Lu","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/(sici)1096-911x(199906)32:6<447::aid-mpo12>3.0.co;2-1","article-title":"Successful treatment of monoclonal, aggressive Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a child with acute lymphoblastic leukemia","volume":"32","author":"Perkkio","year":"1999","journal-title":"Med Pediatr Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/sj.bmt.1702727","article-title":"Epstein-Barr virus-related lymphoproliferative disease complicating childhood acute lymphoblastic leukemia: no recurrence after unrelated donor bone marrow transplantation","volume":"27","author":"Pondarre","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1389200221666200303113456","article-title":"Clinical application of thiopurine pharmacogenomics in pediatrics","volume":"21","author":"Pavlovic","year":"2020","journal-title":"Curr Drug Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tips.2006.06.007","article-title":"TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?","volume":"27","author":"Maitland","year":"2006","journal-title":"Trends Pharmacol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4274\/tjh.2011.0047","article-title":"Central nervous system involvement of epstein barr virus associated lymphoproliferative disorder in a child with acute lymphoblastic leukemia: successful treatment with rituximab and interferon-alpha","volume":"30","author":"Atabay","year":"2013","journal-title":"Turk J Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/cid\/cit391","article-title":"Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1634\/theoncologist.2010-0213","article-title":"Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far","volume":"16","author":"Castillo","year":"2011","journal-title":"Oncologist."},{"key":"B11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3109\/10428194.2011.634045","article-title":"Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004","volume":"53","author":"Taj","year":"2012","journal-title":"Leuk Lymphoma."},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/1096-911X(20010201)36:2<329::AID-MPO1077>3.0.CO","article-title":"Successful treatment of an Epstein-Barr virus-associated B-cell lymphoproliferative disease in a child with acute lymphoblastic leukemia using an anti-CD20 monoclonal antibody","volume":"36","author":"Bernard","year":"2001","journal-title":"Med Pediatr Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/08880018.2019.1637982","article-title":"Iatrogenic immunodeficiency-associated lymphoproliferative disorder in a child with B-cell acute lymphoblastic leukemia","volume":"36","author":"Shahid","year":"2019","journal-title":"Pediatr Hematol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ecco-jcc\/jjx123","article-title":"A severe neonatal lymphopenia associated with administration of azathioprine to the mother in a context of Crohn's Disease","volume":"12","author":"Thomas","year":"2018","journal-title":"J Crohns Colitis."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.881612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T06:56:22Z","timestamp":1651820182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.881612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":15,"alternative-id":["10.3389\/fped.2022.881612"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.881612","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"article-number":"881612"}}